<article title='Recreational_use_of_dextromethorphan'><paragraph><template><target>Use dmy dates</target><arg name="date">December 2010</arg></template><template><target>For</target><arg>general information on this drug, including medical usage</arg><arg>dextromethorphan</arg></template><link><target>File:DXM Doses.jpg</target><part>thumb</part><part>Cough medicine containing dextromethorphan in gel cap form</part></link></paragraph><paragraph><bold><link><target>Dextromethorphan</target></link><space/>(DXM)</bold>, a common<space/><link><target>active ingredient</target></link><space/>found in many over-the-counter<space/><link><target>cough suppressant</target></link><space/>cold medicines, is used as a<space/><link><target>recreational drug use</target><part>recreational drug</part></link><space/>and<space/><link><target>entheogen</target></link><space/>for its<space/><link><target>dissociative</target></link><space/>effects.<extension extension_name='ref' name="cesar"></extension><space/>It has almost no<space/><link><target>psychoactive</target></link><space/>effects at medically recommended doses. Dextromethorphan has powerful<space/><link><target>dissociative</target></link><space/>properties when administered in doses well above those considered therapeutic for cough suppression.<extension extension_name='ref' name="cesar"><template><target>cite web</target><arg name="url">http://www.cesar.umd.edu/cesar/drugs/dxm.asp<space/></arg><arg name="title">Dextromethorphan (DXM) &#124; CESAR<space/></arg><arg name="website">Cesar.umd.edu<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><space/>Recreational use of DXM is sometimes referred to in slang form as &quot;robo-tripping&quot;, whose prefix derives from the<space/><link><target>Robitussin</target></link><space/>brand name, or<space/><italics>Triple Cs,</italics><space/>which derives from the<space/><link><target>Coricidin</target></link><space/>brand (the pills were printed with &quot;CCC&quot; for &quot;Coricidin Cough and Cold&quot; However, this brand presents a danger when used at recreational doses due to the presence of<space/><link><target>Chlorpheniramine</target></link>)</paragraph><paragraph>In over-the-counter formulations, DXM is often combined with<space/><link><target>acetaminophen</target></link><space/>(paracetamol, APAP) to relieve pain and to prevent recreational use<template><target>Citation needed</target><arg name="date">May 2015</arg></template>; however, to achieve DXM's dissociative effects, the maximum daily therapeutic dose of 4000&amp;nbsp;mg of<space/><link><target>Paracetamol</target><part>APAP</part></link><space/>is often exceeded, potentially causing acute or chronic<space/><link><target>liver failure</target></link>, making abuse and subsequent tolerance of products which contain both DXM and APAP potentially fatal.<extension extension_name='ref' name="Cigina"><template><target>cite web</target><arg name="title">DXM APAP<space/></arg><arg name="url">http://www.cigna.com/individualandfamilies/health-and-well-being/hw/medications/acetaminophen-and-dextromethorphan-d03378a1.html<space/></arg><arg name="archiveurl">https://web.archive.org/web/20130106001214/http://www.cigna.com/individualandfamilies/health-and-well-being/hw/medications/acetaminophen-and-dextromethorphan-d03378a1.html<space/></arg><arg name="archivedate">6 January 2013<space/></arg><arg name="publisher">Cigna Health Care<space/></arg><arg name="website">Cigna.com<space/></arg><arg name="accessdate">4 Jan 2012</arg></template></extension></paragraph><paragraph>An online essay first published in 1995 entitled &quot;The DXM FAQ&quot; described dextromethorphans potential for recreational use, and classified its effects into plateaus.<extension extension_name='ref' name="darkridge"><template><target>cite web</target><arg name="url">http://dxm.darkridge.com/faq/contents.html<space/></arg><arg name="title">Darkridge &#124;The Dextromethorphan DXM FAQ<space/></arg><arg name="website">DXM.darkridge.com<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension></paragraph><paragraph>Owing to its recreational use and theft concerns,<template><target>Citation needed</target><arg name="date">October 2008</arg></template><space/>many retailers in the US have moved dextromethorphan-containing products behind the counter so that one must ask a pharmacist to receive them or be 18 years (19 in<space/><link><target>New York</target></link>,<space/><link><target>Nebraska</target></link>,<space/><link><target>Virginia</target></link>, and<space/><link><target>Alabama</target></link>, 21 in<space/><link><target>Mississippi</target></link>) or older to purchase them. Some retailers also give out printed recommendations about the potential for abuse with the purchase of products containing dextromethorphan.</paragraph><heading level='2'>Classification</heading><paragraph>At high doses, dextromethorphan is classified as a dissociative general anesthetic and hallucinogen, similar to the controlled substances<space/><link><target>ketamine</target></link><space/>and<space/><link><target>phencyclidine</target></link><space/>(PCP).<extension extension_name='ref' name="dea1"><template><target>cite web</target><arg name="url">http://www.deadiversion.usdoj.gov/drugs_concern/dextro_m/dextro_m.htm<space/></arg><arg name="archiveurl">https://web.archive.org/web/20101219103019/http://www.deadiversion.usdoj.gov/drugs_concern/dextro_m/dextro_m.htm<space/></arg><arg name="archivedate">19 December 2010<space/></arg><arg name="title">DEXTROMETHORPHAN (Street Names: DXM, CCC, Triple C, Skittles, Robo, Poor Man’s PCP<space/></arg><arg name="website">Deadiversion.usdoj.gov)</arg></template></extension><space/>Also like those drugs, dextromethorphan is an<space/><link><target>NMDA receptor antagonist</target></link>.<extension extension_name='ref' name="webtryp"><template><target>cite press release</target><arg name="url">https://www.erowid.org/psychoactives/research_chems/research_chems_law3.pdf<space/></arg><arg name="title">FORMER MINOTMAN AND INTERNET CHEMICAL COMPANY SENTENCED FOR SELLING DESIGNER AND MISBRANDED DRUGS AND VIOLATING FEDERAL CUSTOMS LAWS<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="date">30 June 2006<space/></arg><arg name="format">PDF<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><extension extension_name='ref' name="Dxm_Hallucinogen"><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_effects.shtml<space/></arg><arg name="title">Erowid DXM Vault : Effects<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><space/>Dextromethorphan generally does not produce withdrawal symptoms characteristic of<space/><link><target>physical dependence</target></link>-inducing substances, but there have been cases of<space/><link><target>psychological dependence</target></link>. Due to dextromethorphan's SSRI (selective serotonin re-uptake inhibitor)-like action, the sudden cessation of recreational dosing in tolerant individuals can result in mental and physical withdrawal symptoms similar to the withdrawal from SSRIs. These withdrawal effects can manifest as psychological effects, including depression, irritability, cravings, and as physical effects, including lethargy, body aches, and a sensation of unpleasant tingling, not unlike a mild &quot;electric shock&quot;.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.drugabusehelp.com/drugs/dxm/<space/></arg><arg name="title">Drug Abuse Help: DXM Information<space/></arg><arg name="website">Drugabusehelp.com<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.info-drug-rehab.com/dxm.html<space/></arg><arg name="archiveurl">https://web.archive.org/web/20130917011848/http://info-drug-rehab.com/dxm.html<space/></arg><arg name="archivedate">17 September 2013<space/></arg><arg name="title">:: Cough Syrup and Dextromethorphan (DXM) Addiction and Abuse – Drug Rehab Information ::<space/></arg><arg name="website">Info-drug-rehab.com</arg></template></extension></paragraph><heading level='2'>Effects</heading><paragraph>Dextromethorphan's effects have been divided into four plateaus. The first plateau (1.5 to 2.5&amp;nbsp;mg/kg) is described as having euphoria, auditory changes, and change in perception of gravity. The second plateau (2.5 to 7.5&amp;nbsp;mg/kg) causes intense<space/><link><target>euphoria</target></link>, vivid imagination, and<space/><link><target>closed-eye hallucination</target><trail>s</trail></link><space/>may occur. The third and fourth plateaus (600&amp;nbsp;mg, or 7.5&amp;nbsp;mg/kg and over) cause profound alterations in consciousness, and users often report out-of-body experiences or temporary<space/><link><target>psychosis</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Bornstein<space/></arg><arg name="first1">S<space/></arg><arg name="last2">Czermak<space/></arg><arg name="first2">M<space/></arg><arg name="last3">Postel<space/></arg><arg name="first3">J<space/></arg><arg name="title">Apropos of a case of voluntary medicinal intoxication with dextromethorphan hydrobromide<space/></arg><arg name="journal">Annales Medico-Psychologiques<space/></arg><arg name="volume">1<space/></arg><arg name="issue">3<space/></arg><arg name="year">1968<space/></arg><arg name="pages">447–451<space/></arg><arg name="pmid">5670018</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Dodds<space/></arg><arg name="first1">A<space/></arg><arg name="last2">Revai<space/></arg><arg name="first2">E<space/></arg><arg name="title">Toxic psychosis due to dextromethorphan<space/></arg><arg name="journal">Med J Aust<space/></arg><arg name="year">1967<space/></arg><arg name="volume">2<space/></arg><arg name="page">231</arg></template></extension><space/><link><target>Flanging</target></link><space/>(speeding up or slowing down) of sensory input is also a characteristic effect of recreational use.</paragraph><paragraph>There is also a marked difference between dextromethorphan hydrobromide, contained in most cough suppressant preparations, and dextromethorphan polistirex, contained in the brand name preparation Delsym. Polistirex is a polymer that is bonded to the dextromethorphan that requires more time for the stomach to digest it as it requires that an<space/><link><target>ion exchange</target></link><space/>reaction take place prior to its dissolution into the blood. Because of this, dextromethorphan polistirex takes considerably longer to absorb, resulting in more gradual and longer lasting effects reminiscent of time release pills. As a cough suppressant, the polistirex version lasts up to 12 hours. This duration also holds true when used recreationally.</paragraph><paragraph>In 1981, a paper by Gosselin estimated that the lethal dose is between 50 and 500&amp;nbsp;mg/kg. Doses as high as 1520&amp;nbsp;mg/kg are taken by some recreational users. It is suggested by a single case study that the antidote to dextromethorphan overdose is<space/><link><target>naloxone</target></link>, administered<space/><link><target>intravenously</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Schneider<space/></arg><arg name="first1">SM<space/></arg><arg name="last2">Michelson<space/></arg><arg name="first2">EA<space/></arg><arg name="title">Dextromethorphan poisoning reversed by naloxone<space/></arg><arg name="journal">Am. J. Emerg. Med<space/></arg><arg name="year">1991<space/></arg><arg name="volume">9<space/></arg><arg name="issue">3<space/></arg><arg name="pmid">2018593<space/></arg><arg name="pages">237–238<space/></arg><arg name="doi">10.1016/0735-6757(91)90085-X</arg></template></extension></paragraph><paragraph>In addition to producing PCP-like mental effects, high doses may cause a false-positive result for PCP and<space/><link><target>opiates</target></link><space/>in some drug tests.<extension extension_name='ref' name="dea1"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_testing.shtml<space/></arg><arg name="title">Erowid DXM Vault : Drug Tests<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension></paragraph><heading level='2'>Risks associated with use</heading><paragraph>Dextromethorphan has not been shown to cause<space/><link><target>vacuolization</target></link><space/>in animals, also known as<space/><link><target>Olney's lesions</target></link>, despite early speculation that it may, due to similarities with phencyclidine (PCP).<extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_health2.shtml<space/></arg><arg name="title">The Bad News Isn't In<space/></arg><arg name="last">Anderson<space/></arg><arg name="first">Cliff<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><space/>In rats,<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Hashimoto<space/></arg><arg name="first1">K<space/></arg><arg name="last2">Tomitaka<space/></arg><arg name="first2">S<space/></arg><arg name="last3">Narita<space/></arg><arg name="first3">N<space/></arg><arg name="last4">Minabe<space/></arg><arg name="first4">Y<space/></arg><arg name="last5">Iyo<space/></arg><arg name="first5">M<space/></arg><arg name="last6">Fukui<space/></arg><arg name="first6">S<space/></arg><arg name="title">Induction of [[heat shock protein]] [[Hsp70]] in rat [[retrosplenial cortex]] following administration of [[dextromethorphan]]<space/></arg><arg name="journal">Environmental Toxicology and Pharmacology<space/></arg><arg name="volume">1<space/></arg><arg name="issue">4<space/></arg><arg name="pages">235–239<space/></arg><arg name="year">1996<space/></arg><arg name="doi">10.1016/1382-6689(96)00016-6<space/></arg><arg name="pmid">21781688</arg></template></extension><space/>oral administration of dextromethorphan did not cause vacuolization in laboratory tests.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Carliss<space/></arg><arg name="first1">RD<space/></arg><arg name="last2">Radovsky<space/></arg><arg name="first2">A<space/></arg><arg name="last3">Chengelis<space/></arg><arg name="first3">CP<space/></arg><arg name="last4">O'neill<space/></arg><arg name="first4">TP<space/></arg><arg name="last5">Shuey<space/></arg><arg name="first5">DL<space/></arg><arg name="title">Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain<space/></arg><arg name="journal">NeuroToxicology<space/></arg><arg name="volume">28<space/></arg><arg name="issue">4<space/></arg><arg name="page">813<space/></arg><arg name="year">2007<space/></arg><arg name="pmid">17573115<space/></arg><arg name="doi">10.1016/j.neuro.2007.03.009</arg></template></extension><space/>Oral administration of dextromethorphan repeatedly during adolescence, however, has been shown to impair learning in those rats during adulthood.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Zhang<space/></arg><arg name="first1">TY<space/></arg><arg name="last2">Cho<space/></arg><arg name="first2">HJ<space/></arg><arg name="last3">Lee<space/></arg><arg name="first3">S<space/></arg><arg name="last4">Lee<space/></arg><arg name="first4">JH<space/></arg><arg name="last5">Choi<space/></arg><arg name="first5">SH<space/></arg><arg name="last6">Ryu<space/></arg><arg name="first6">V<space/></arg><arg name="last7">Yoo<space/></arg><arg name="first7">SB<space/></arg><arg name="last8">Lee<space/></arg><arg name="first8">JY<space/></arg><arg name="last9">Kim<space/></arg><arg name="first9">DG<space/></arg><arg name="last10">Jahng<space/></arg><arg name="first10">JW<space/></arg><arg name="display-authors">6<space/></arg><arg name="title">Impairments in water maze learning of aged rats that received dextromethorphan repeatedly during adolescent period<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">191<space/></arg><arg name="issue">1<space/></arg><arg name="pages">171–9<space/></arg><arg name="year">2006<space/></arg><arg name="doi">10.1007/s00213-006-0548-3<space/></arg><arg name="pmid">17021924</arg></template></extension><space/>The occurrence of Olney's lesions in humans, however, has not been proven or disproven. William E. White, author of the &quot;DXM FAQ&quot;, has compiled informal research from correspondence with dextromethorphan users suggesting that heavy abuse may result in various deficits corresponding to the brain areas affected by Olney's lesions; these include loss of<space/><link><target>episodic memory</target></link>, decline in ability to learn, abnormalities in some aspects of visual processing, and deficits of abstract language comprehension.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.dextroverse.org/txt/olney.txt<space/></arg><arg name="title">Erowid DXM Vault : This is your brain on dissociatives, the bad news is finally in<space/></arg><arg name="last">White<space/></arg><arg name="first">William E.<space/></arg><arg name="website">Dextroverse.com<space/></arg><arg name="accessdate">14 February 2014<space/></arg><arg name="format">TXT</arg></template></extension><space/>In 2004, however, White retracted the article in which he made these claims.<extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_health3.shtml<space/></arg><arg name="title">Erowid DXM Vault : Response to "The Bad News Isn't In": Please Pass The Crow, by William E. White<space/></arg><arg name="last">White<space/></arg><arg name="first">William E.<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension></paragraph><paragraph>A formal survey of dextromethorphan users<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Ziaee<space/></arg><arg name="first1">V<space/></arg><arg name="last2">Akbari Hamed<space/></arg><arg name="first2">E<space/></arg><arg name="last3">Hoshmand<space/></arg><arg name="first3">A<space/></arg><arg name="last4">Amini<space/></arg><arg name="first4">H<space/></arg><arg name="last5">Kebriaeizadeh<space/></arg><arg name="first5">A<space/></arg><arg name="last6">Saman<space/></arg><arg name="first6">K<space/></arg><arg name="title">Side effects of dextromethorphan abuse, a case series<space/></arg><arg name="journal">Addictive Behavior<space/></arg><arg name="date">September 2005<space/></arg><arg name="volume">30<space/></arg><arg name="issue">8<space/></arg><arg name="pages">1607–13<space/></arg><arg name="pmid">16122622<space/></arg><arg name="doi">10.1016/j.addbeh.2005.02.005</arg></template></extension><space/>showed that more than half of users reported experience of the following withdrawal-symptoms individually for the first week after long-term/addictive dextromethorphan use:<space/><link><target>fatigue (medical)</target><part>fatigue</part></link>,<space/><link><target>apathy</target></link>,<space/><link><target>Flashback (psychology)</target><part>flashbacks</part></link>, and<space/><link><target>constipation</target></link>. Over a quarter reported<space/><link><target>insomnia</target></link>,<space/><link><target>nightmares</target></link>,<space/><link><target>anhedonia</target></link>, impaired memory, attention deficit and decreased<space/><link><target>libido</target></link>. Rarer side effects included<space/><link><target>panic attacks</target></link>, impaired learning,<space/><link><target>tremor</target></link>,<space/><link><target>jaundice</target></link>,<space/><link><target>urticaria</target></link><space/>(hives) and<space/><link><target>myalgia</target></link>. Frequent and long-term usage at very high doses could possibly lead to<space/><link><target>toxic psychosis</target></link><space/>and other permanent psychological problems. It is important to note that responsible DXM use has not been shown to cause the above issues.<space/><extension extension_name='ref' name="cesar"></extension></paragraph><paragraph>Erectile dysfunction and diminished libido can be a longer-term effect (years to decades) of many narcotic analgesics due to development of central<space/><link><target>hypogonadism</target></link>; this appears especially common in individuals with significant<space/><link><target>melanin</target></link><space/>deficiencies, as the hormones tied to melanin production affect the absorption and conversion of these analgesics into progesterone.<extension extension_name='ref'>Advanced Hormone Physiology<template><target>full</target><arg name="date">February 2014</arg></template></extension><space/>Additionally, the haplotypes of about 48% of the indigenous population of<space/><link><target>United Kingdom</target><part>Britain</part></link><space/>aggravate the condition, as the E647 sequence underwent epigenetic degradation and became a<space/><link><target>pseudogene</target></link>. The chance of vulnerability is doubled for males, as the critical sequence is located on the X chromosome.<extension extension_name='ref'>Busch and Grenfield, et al.<template><target>full</target><arg name="date">February 2014</arg></template></extension></paragraph><paragraph>Misuse of multi-symptom cold medications, rather than using a cough suppressant whose sole active ingredient is dextromethorphan, carries significant risk of fatality or serious illness. Multi-symptom cold medicines contain other active ingredients, such as<space/><link><target>paracetamol</target></link><space/>(acetaminophen),<space/><link><target>chlorpheniramine</target></link>, and<space/><link><target>phenylephrine</target></link>, any of which can cause permanent bodily damage such as kidney failure, or even death, if taken on the generally accepted recreational dosing scale of dextromethorphan.<space/><link><target>Sorbitol</target></link>, an artificial sweetener found in many cough syrups containing dextromethorphan, can also have negative side effects including diarrhea and nausea when taken at recreational dosages of dextromethorphan.<extension extension_name='ref' name="kirages"><template><target>cite journal</target><arg name="last1">Kirages<space/></arg><arg name="first1">T<space/></arg><arg name="last2">Sulé<space/></arg><arg name="first2">H<space/></arg><arg name="last3">Mycyk<space/></arg><arg name="first3">M<space/></arg><arg name="title">Severe manifestations of coricidin intoxication<space/></arg><arg name="journal">Am J Emerg Med<space/></arg><arg name="volume">21<space/></arg><arg name="issue">6<space/></arg><arg name="pages">473–5<space/></arg><arg name="year">2003<space/></arg><arg name="pmid">14574654<space/></arg><arg name="doi">10.1016/S0735-6757(03)00168-2</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kintz<space/></arg><arg name="first1">P<space/></arg><arg name="last2">Mangin<space/></arg><arg name="first2">P<space/></arg><arg name="title">Toxicological findings in a death involving dextromethorphan and terfenadine<space/></arg><arg name="journal">Am J Forensic Med Pathol<space/></arg><arg name="date">December 1992<space/></arg><arg name="volume">13<space/></arg><arg name="issue">4<space/></arg><arg name="pages">351–352<space/></arg><arg name="doi">10.1097/00000433-199212000-00018<space/></arg><arg name="pmid">1288270</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_info2.shtml<space/></arg><arg name="title">Erowid DXM Vault : Guide to DXM in Non-Prescription Drugs<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><space/><link><target>Guaifenesin</target></link>, an<space/><link><target>expectorant</target></link><space/>commonly accompanying dextromethorphan in cough preparations, can cause unpleasant symptoms including<space/><link><target>vomiting</target></link>,<space/><link><target>nausea</target></link>, and<space/><link><target>headache</target></link>.</paragraph><paragraph>Combining dextromethorphan with other substances can compound risks.<space/><link><target>stimulants</target><part>CNS stimulants</part></link><space/>such as<space/><link><target>amphetamine</target></link><space/>and/or<space/><link><target>cocaine</target></link><space/>can cause a dangerous rise in blood pressure and heart rate.<space/><link><target>CNS depressant</target><trail>s</trail></link><space/>such as<space/><link><target>ethanol</target></link><space/>(drinking alcohol) will have a combined depressant effect, which can cause a decreased<space/><link><target>Breathing</target><part>respiratory</part></link><space/>rate. Combining dextromethorphan with other<space/><link><target>CYP2D6 inhibitor</target><part>CYP2D6 substrates</part></link><space/>can cause both drugs to build to dangerous levels in the bloodstream.<extension extension_name='ref' name="nhtsa"><template><target>cite web</target><arg name="url">http://www.nhtsa.gov/PEOPLE/injury/research/job185drugs/dextromethorphan.htm<space/></arg><arg name="title">Drugs and Human Performance FACT SHEETS – Dextromethorphan<space/></arg><arg name="publisher">National Highway Traffic Safety Administration<space/></arg><arg name="website">Nhsta.gov</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/faq/dxm_side_effects.shtml<space/></arg><arg name="title">Erowid DXM Vault : DXM FAQ – Side Effects<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension></paragraph><paragraph>Combining dextromethorphan with other<space/><link><target>serotonergic</target></link><space/>drugs could possibly cause<space/><link><target>serotonin toxicity</target></link>, an excess of serotonergic activity in the<space/><link><target>central nervous system</target></link><space/>(CNS) and<space/><link><target>peripheral nervous system</target></link><space/>(PNS).</paragraph><heading level='2'>Pharmacology</heading><paragraph>Dextromethorphan's hallucinogenic and dissociative effects can be attributed largely to<space/><link><target>dextrorphan</target></link><space/>(DXO), a<space/><link><target>metabolite</target></link><space/>produced when dextromethorphan is metabolized by the body. Both dextrorphan<space/><italics>and</italics><space/>dextromethorphan are<space/><link><target>NMDA receptor antagonist</target><trail>s</trail></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Helmy<space/></arg><arg name="first1">SAK<space/></arg><arg name="last2">Bali<space/></arg><arg name="first2">A<space/></arg><arg name="url">http://cat.inist.fr/?aModele</arg><arg name="publisher">Cat.Inist.fr<space/></arg><arg name="title">The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements<space/></arg><arg name="journal">Anesthesia and Analgesia<space/></arg><arg name="year">2002<space/></arg><arg name="volume">92<space/></arg><arg name="issue">3<space/></arg><arg name="pages">739–744<space/></arg><arg name="language">French, English<space/></arg><arg name="issn">0003-2999<space/></arg><arg name="doi">10.1213/00000539-200103000-00035</arg></template></extension><space/>like the dissociative hallucinogenic drugs<space/><link><target>ketamine</target></link><space/>and<space/><link><target>phencyclidine</target></link><space/>(PCP), although dextrorphan is more potent than its &quot;parent molecule&quot; dextromethorphan.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Pechnick<space/></arg><arg name="first1">RN<space/></arg><arg name="last2">Poland<space/></arg><arg name="first2">RE<space/></arg><arg name="url">http://jpet.aspetjournals.org/cgi/content/full/309/2/515?ijkey</arg><arg name="title">Comparison of the Effects of Dextromethorphan, Dextrorphan, and Levorphanol on the Hypothalamo-Pituitary-Adrenal Axis – Pechnick and Poland<space/></arg><arg name="journal">Journal of Pharmacology And Experimental Therapeutics<space/></arg><arg name="volume">309<space/></arg><arg name="issue">2<space/></arg><arg name="page">515<space/></arg><arg name="doi">10.1124/jpet.103.060038<space/></arg><arg name="pmid">14742749</arg></template><space/><template><target>open access</target></template></extension></paragraph><paragraph>As NMDA receptor antagonists, dextrorphan and dextromethorphan inhibit the excitatory amino acid and<space/><link><target>neurotransmitter</target></link><space/><link><target>glutamate</target></link><space/>in the brain. This can effectively slow, or even shut down certain neural pathways, preventing areas of the brain from communicating with each other. This leaves the user feeling dissociated or disconnected, experienced as<space/><link><target>brain fog</target></link><space/>or<space/><link><target>derealization</target></link>.<extension extension_name='ref' name="Muir KW and Lees KR"><template><target>cite journal</target><arg name="last1">Muir<space/></arg><arg name="first1">KW<space/></arg><arg name="last2">Lees<space/></arg><arg name="first2">KR<space/></arg><arg name="title">Clinical experience with excitatory amino acid antagonist drugs<space/></arg><arg name="journal">Stroke<space/></arg><arg name="volume">26<space/></arg><arg name="issue">3<space/></arg><arg name="pages">503–513<space/></arg><arg name="date">1995<space/></arg><arg name="url">http://stroke.ahajournals.org/cgi/content/full/26/3/503<space/></arg><arg name="doi">10.1161/01.STR.26.3.503<space/></arg><arg name="pmid">7886734</arg></template><space/><template><target>open access</target></template></extension><extension extension_name='ref' name="Kristensen "><template><target>cite journal</target><arg name="last">Kristensen<space/></arg><arg name="first">JD<space/></arg><arg name="last2">Svensson<space/></arg><arg name="first2">B<space/></arg><arg name="last3">Gordh Jr.<space/></arg><arg name="first3">T<space/></arg><arg name="title">The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans<space/></arg><arg name="journal">Pain<space/></arg><arg name="volume">51<space/></arg><arg name="issue">2<space/></arg><arg name="pages">249–253<space/></arg><arg name="year">1992<space/></arg><arg name="url"><space/></arg><arg name="doi">10.1016/0304-3959(92)90266-E<space/></arg><arg name="pmid">1484720</arg></template></extension></paragraph><paragraph>Dextromethorphan's euphoric effects have sometimes been attributed to an increase in<space/><link><target>dopamine</target></link><space/>levels, since such an increase generally correlates with pleasurable responses to drug, as is observed with some clinical<space/><link><target>antidepressants</target></link>, as well as some recreational drugs. However, the effects of dextrorphan and dextromethorphan, and other NMDA receptor antagonists, on dopamine levels is a disputed subject. Studies show that the NMDA receptor antagonists ketamine and PCP do raise dopamine levels,<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kapur<space/></arg><arg name="first1">S<space/></arg><arg name="last2">Seeman<space/></arg><arg name="first2">P<space/></arg><arg name="url">http://www.nature.com/mp/journal/v7/n8/full/4001093a.html<space/></arg><arg name="title">NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptors implications for models of schizophrenia<space/></arg><arg name="journal">Molecular Psychiatry<space/></arg><arg name="year">2002<space/></arg><arg name="volume">7<space/></arg><arg name="issue">8<space/></arg><arg name="pages">837–844<space/></arg><arg name="doi">10.1038/sj.mp.4001093<space/></arg><arg name="pmid">12232776</arg></template><space/><template><target>open access</target></template></extension><extension extension_name='ref' name="jofns"><template><target>cite journal</target><arg name="last1">Verma<space/></arg><arg name="first1">A<space/></arg><arg name="last2">Moghaddam<space/></arg><arg name="first2">B<space/></arg><arg name="title">NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine<space/></arg><arg name="journal">Journal of Neuroscience<space/></arg><arg name="date">16 January 1996<space/></arg><arg name="volume">1<space/></arg><arg name="pages">373–9<space/></arg><arg name="pmid">8613804<space/></arg><arg name="issue">1</arg></template><space/><template><target>open access</target></template></extension><space/>although other studies show that another NMDA receptor antagonist<space/><link><target>dizocilpine</target></link><space/>has no effect on dopamine levels. Some findings even suggest that dextromethorphan can actually<space/><italics>counter</italics><space/>the dopamine-increasing effect caused by<space/><link><target>morphine</target></link>.<extension extension_name='ref' name="nhtsa"></extension><extension extension_name='ref' name="Steinmiller CL et al."><template><target>cite journal</target><arg name="last">Steinmiller<space/></arg><arg name="first">CL<space/></arg><arg name="last2">Maisonneuve<space/></arg><arg name="first2">IM<space/></arg><arg name="last3">Glick<space/></arg><arg name="first3">SD<space/></arg><arg name="title">Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine<space/></arg><arg name="journal">Pharmacol Biochem Behav<space/></arg><arg name="volume">74<space/></arg><arg name="issue">4<space/></arg><arg name="pages">803–10<space/></arg><arg name="publisher">Center for Neuropharmacology and Neuroscience (MC-136)<space/></arg><arg name="year">2003<space/></arg><arg name="url"><space/></arg><arg name="doi">10.1016/S0091-3057(02)01080-8<space/></arg><arg name="pmid">12667894</arg></template></extension><extension extension_name='ref' name="Carrozza DP et al."><template><target>cite journal</target><arg name="last">Carrozza<space/></arg><arg name="first">DP<space/></arg><arg name="last2">Ferraro<space/></arg><arg name="first2">TN<space/></arg><arg name="last3">Golden<space/></arg><arg name="first3">GT<space/></arg><arg name="last4">Reyes<space/></arg><arg name="first4">PF<space/></arg><arg name="last5">Hare<space/></arg><arg name="first5">TA<space/></arg><arg name="title">In vivo modulation of excitatory amino acid receptors: microdialysis studies on N-methyl-D-aspartate-evoked striatal dopamine release and effects of antagonists<space/></arg><arg name="journal">Brain Res<space/></arg><arg name="volume">574<space/></arg><arg name="issue">1–2<space/></arg><arg name="pages">42–8<space/></arg><arg name="date">1992<space/></arg><arg name="url"><space/></arg><arg name="doi">10.1016/0006-8993(92)90797-D<space/></arg><arg name="pmid">1353403</arg></template></extension><extension extension_name='ref' name="Huang EY et al."><template><target>cite journal</target><arg name="last">Huang<space/></arg><arg name="first">EY<space/></arg><arg name="last2">Liu<space/></arg><arg name="first2">TC<space/></arg><arg name="last3">Tao<space/></arg><arg name="first3">PL<space/></arg><arg name="title">Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens<space/></arg><arg name="journal">Brain Res<space/></arg><arg name="volume">368<space/></arg><arg name="issue">5<space/></arg><arg name="pages">386–92<space/></arg><arg name="publisher"><space/></arg><arg name="year">2003<space/></arg><arg name="url"><space/></arg><arg name="doi">10.1007/s00210-003-0803-7<space/></arg><arg name="pmid">14564449</arg></template></extension><space/>Due to these conflicting results, the actual effect of dextromethorphan on dopamine levels remain undetermined.</paragraph><heading level='2'>Legality</heading><paragraph>Antitussive preparations containing dextromethorphan are legal to purchase from pharmacies in most countries, with some exceptions being UAE, Sweden,<extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.erowid.org/chemicals/dxm/dxm_law.shtml<space/></arg><arg name="title">Erowid DXM Vault : Legal Status<space/></arg><arg name="publisher">Erowid<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension><space/>Estonia and Latvia.<template><target>citation needed</target><arg name="date">August 2009</arg></template></paragraph><paragraph>In<space/><link><target>Russia</target></link>, dextromethorphan (commonly sold under the brand names Tussin+ and Glycodin) is a Schedule III controlled substance and is placed in the same list as<space/><link><target>benzodiazepines</target></link><space/>and the majority of<space/><link><target>barbiturates</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://base.garant.ru/12112176<space/></arg><arg name="title">Decision of the Government of the Russian Federation No. 681 of June 30, 1998 on the Approval of the List of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (with Amendments and Additions)<space/></arg><arg name="website">Base.garant.ru<space/></arg><arg name="language">Russian<space/></arg><arg name="accessdate">14 February 2014</arg></template></extension></paragraph><heading level='3'>United States</heading><paragraph>No legal distinction currently exists in the United States between medical and recreational use, sale, or purchase. Some states and store chains have implemented restrictions, such as requiring signatures for DXM sale, limiting quantities allowable for purchase, and requiring that purchasers be over the age of majority in their state.</paragraph><paragraph>The sale of dextromethorphan in its pure powder form may incur penalties, although no explicit law exists prohibiting its sale or possession, other than in the state of Illinois. There have been cases of individuals being sentenced to time in prison and other penalties for selling pure dextromethorphan in this form, because of the incidental violation of more general laws for the sale of legitimate drugs such as resale of a medication without proper warning labels.<extension extension_name='ref' name="webtryp"></extension></paragraph><paragraph>Dextromethorphan was excluded from the<space/><link><target>Controlled Substances Act</target></link><space/>(CSA) of 1970 and was specifically excluded from the<space/><link><target>Single Convention on Narcotic Drugs</target></link>. Dextromethorphan is still excluded from the CSA (as of 2010); however, officials have warned that it could still be added if increased abuse warrants its scheduling.<extension extension_name='ref' name="dea1"></extension><space/>The motivation behind its exclusion from the CSA was that, under the CSA, all<space/><link><target>Chirality (chemistry)</target><part>optical isomers</part></link><space/>of listed Schedule II opiates are automatically<space/><link><target>List of Schedule II drugs (US)</target><part>Schedule II substances</part></link>. Since dextromethorphan is an optical isomer of the Schedule II opiate<space/><link><target>levomethorphan</target></link><space/>(but does not act like an opiate), an exemption was necessary to keep it a non-controlled substance. The<space/><link><target>Federal Analog Act</target></link><space/>does not apply to dextromethorphan because a new drug application has been filed for it.</paragraph><heading level='3'>Indonesia</heading><paragraph>After previously available over the counter, The National Agency of Drug and Food Control of Republic of<space/><link><target>Indonesia</target></link><space/>(BPOM-RI) prohibit single component dextromethorphan drug sales with or without prescription. Indonesia is the only country in the world that makes single-component dextromethorphan illegal even by prescription<extension extension_name='ref'>http://nasional.news.viva.co.id/news/read/506418-bpom-tetap-batalkan-izin-edar-obat-dekstrometorfan<template><target>full</target><arg name="date">April 2015</arg></template></extension><space/>and violators may be prosecuted by law. Indonesian National Narcotic Bureau (BNN RI) has even threatened to revoke pharmacies' and drug stores' licenses if they still stock dextromethorphan, and will notify the police for criminal prosecution.<extension extension_name='ref'>http://daerah.sindonews.com/read/878465/21/bnn-ancam-tutup-apotek-penjual-dextromethorphan-1404129585<template><target>full</target><arg name="date">April 2015</arg></template></extension><space/>As a result of this regulation, 130 drugs have been withdrawn from the market, but drugs containing multicomponent dextromethorphan can be sold over the counter.<extension extension_name='ref'>http://www.pom.go.id/files/edaran_dektrome_2013.pdf<template><target>full</target><arg name="date">April 2015</arg></template></extension><space/>In its official press release, BPOM-RI also stated that dextromethorphan is often used as a substitute for marijuana, amphetamine, and heroin by drug abusers, and its use as an antitussive is less beneficial nowadays<extension extension_name='ref'>http://www.pom.go.id/new/index.php/view/pers/231/Penjelasan-Terkait-Produk-Obat-Batuk-yang-Beredar--dan--Mengandung-Bahan-Dekstrometorfan-Tunggal-.html<template><target>full</target><arg name="date">April 2015</arg></template></extension></paragraph><paragraph>The Director of Narcotics, Psychotropics, and Addictive Substances Control (NAPZA) BPOM-RI, Dr. Danardi Sosrosumihardjo, SpKJ, explains that dextromethorphan, morphine, and heroin are derived from the same tree, and states the effect of dextromethorphan to be equivalent to 1/100 of morphine and injected heroin.<extension extension_name='ref'>http://health.liputan6.com/read/2058886/ini-alasan-130-obat-batuk-ditarik-dari-pasaran<template><target>full</target><arg name="date">April 2015</arg></template></extension>By contrast, the Deputy of Therapeutic Product and NAPZA Supervision BPOM-RI, Dra. Antonia Retno Tyas Utami, Apt. MEpid., states that dextromethorphan, being chemically similar to morphine, has a much more dangerous and direct effect to the central nervous system, thus causing mental breakdown in the user. She also claimed, without citing any prior scientific study or review, that unlike morphine users, dextrometorphan users cannot be rehabilitated.<extension extension_name='ref'>http://health.liputan6.com/read/708598/dibanding-morfin-obat-batuk-berdekstro-lebih-mematikan<template><target>full</target><arg name="date">April 2015</arg></template></extension><space/>This claim is contradicted by numerous scientific studies which show that<space/><link><target>naloxone</target></link><space/>alone offers effective treatment and promising therapy results in treating dextromethorphan addiction and poisoning.<extension extension_name='ref' name="pmid2018593"><template><target>cite journal</target><arg name="doi">10.1016/0735-6757(91)90085-X<space/></arg><arg name="pmid">2018593<space/></arg><arg name="title">Dextromethorphan poisoning reversed by naloxone<space/></arg><arg name="journal">The American Journal of Emergency Medicine<space/></arg><arg name="volume">9<space/></arg><arg name="issue">3<space/></arg><arg name="pages">237–8<space/></arg><arg name="year">1991<space/></arg><arg name="last1">Schneider<space/></arg><arg name="first1">Sandra M.<space/></arg><arg name="last2">Michelson<space/></arg><arg name="first2">Edward A.<space/></arg><arg name="last3">Boucek<space/></arg><arg name="first3">Charles D.<space/></arg><arg name="last4">Ilkhanipour<space/></arg><arg name="first4">Kaveh<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="pmid">840529<space/></arg><arg name="url">http://pediatrics.aappublications.org/content/59/1/117.short<space/></arg><arg name="year">1977<space/></arg><arg name="author1">Shaul<space/></arg><arg name="first1">W. L.<space/></arg><arg name="title">Dextromethorphan toxicity: Reversal by naloxone<space/></arg><arg name="journal">Pediatrics<space/></arg><arg name="volume">59<space/></arg><arg name="issue">1<space/></arg><arg name="pages">117–8<space/></arg><arg name="last2">Wandell<space/></arg><arg name="first2">M<space/></arg><arg name="last3">Robertson<space/></arg><arg name="first3">W. O.<space/></arg></template></extension><extension extension_name='ref' name="pmid8895234"><template><target>cite journal</target><arg name="doi">10.1016/0304-3959(96)81972-5<space/></arg><arg name="pmid">8895234<space/></arg><arg name="title">Continuous co-administration of dextromethorphan or MK-801 with morphine: Attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance<space/></arg><arg name="journal">Pain<space/></arg><arg name="volume">67<space/></arg><arg name="issue">1<space/></arg><arg name="pages">79–88<space/></arg><arg name="year">1996<space/></arg><arg name="last1">Manning<space/></arg><arg name="first1">Barton H.<space/></arg><arg name="last2">Mao<space/></arg><arg name="first2">Jianren<space/></arg><arg name="last3">Frenk<space/></arg><arg name="first3">Hanan<space/></arg><arg name="last4">Price<space/></arg><arg name="first4">Donald D.<space/></arg><arg name="last5">Mayer<space/></arg><arg name="first5">David J.<space/></arg></template></extension><space/>Dra. Antonia Retno Tyas Utami also claimed high rates of dextromethorphan abuse, including fatalities, in Indonesia and to be further put in question suggest that<space/><link><target>codeine</target></link>, despite being a more physically addictive -opioid class antitussive, be made available as an alternative to dextromethorphan.<extension extension_name='ref'>http://health.kompas.com/read/2013/10/01/1618072/BPOM.akan.Tarik.Pil.Dekstro<template><target>full</target><arg name="date">April 2015</arg></template></extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Dissociative drug</target></link><list type='bullet'><listitem><link><target>Dextrorphan</target></link></listitem><listitem><link><target>Dextromethorphan</target></link></listitem><listitem><link><target>Ketamine</target></link></listitem><listitem><link><target>Nitrous oxide</target></link></listitem><listitem><link><target>Phencyclidine</target></link><space/>(PCP)</listitem></list></listitem><listitem><link><target>Hallucinogen</target></link></listitem><listitem><link><target>NMDA receptor antagonist</target></link></listitem><listitem><link><target>Psychedelic drug</target></link></listitem><listitem><link><target>Purple drank</target></link></listitem><listitem><link><target>Sigma agonist</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>2</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.dextroverse.org/'>Dextroverse</link></listitem><listitem>[//www.erowid.org/chemicals/dxm/dxm_article1.shtml The Electric Cough-Syrup Acid Test by Jim Hogshire from Harper's]</listitem><listitem>[//www.erowid.org/chemicals/dxm/dxm.shtml Erowid Dextromethorphan Vault]</listitem></list><paragraph><template><target>Dissociative psychedelics</target></template></paragraph><paragraph><link><target>Category:Dissociative drugs</target></link><link><target>Category:Drug culture</target></link></paragraph></article>